Back to top
more

Armata Pharmaceuticals (ARMP)

(Delayed Data from AMEX)

$2.56 USD

2.56
2,066

+0.02 (0.59%)

Updated Aug 8, 2024 10:00 AM ET

After-Market: $2.61 +0.05 (1.95%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Wall Street Analysts Believe Armata Pharmaceuticals, Inc. (ARMP) Could Rally 47%: Here's is How to Trade

The mean of analysts' price targets for Armata Pharmaceuticals, Inc. (ARMP) points to a 46.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

What Makes Armata Pharmaceuticals, Inc. (ARMP) a New Buy Stock

Armata Pharmaceuticals, Inc. (ARMP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Armata Pharmaceuticals, Inc. (ARMP) Reports Q3 Loss, Tops Revenue Estimates

Armata Pharmaceuticals, Inc. (ARMP) delivered earnings and revenue surprises of 15.38% and 23.25%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Armata Pharmaceuticals, Inc. (ARMP) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Armata Pharmaceuticals, Inc. (ARMP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Armata Pharmaceuticals, Inc. (ARMP) Reports Q2 Loss, Tops Revenue Estimates

Armata Pharmaceuticals, Inc. (ARMP) delivered earnings and revenue surprises of 0.00% and 42.44%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Will Armata Pharmaceuticals, Inc. (ARMP) Report Negative Q2 Earnings? What You Should Know

Armata Pharmaceuticals, Inc. (ARMP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Armata's AP-PA02 Gets IND Clearance by FDA to Initiate Study

Armata's (ARMP) AP-PA02 IND application gets clearance from the FDA to initiate a phase Ib/IIa study for the treatment of Pseudomonas aeruginosa infections.

Company News for Jun 18, 2020

Companies in the news are: WATT, ARMP, MGEN, CEMI

Company News For Jan 29, 2020

Companies In The News Are: ARMP, GGG, MMM and OBCI